Skip to content
Catalyst

sn-glycerol 3-phosphocholineFinding

Sn-glycerol 3-phosphocholine has no detected effect on Hamilton Depression Rating Scale (HDRS) total score

no difference foundModerate evidenceFinding

01 · The sentence it was drawn from

“The HDRS was significantly decreased in both the choline alphoscerate (15.9 ± 6.5 to 12.6 ± 5.8, p = 0.001) and placebo (15.4 ± 4.7 to 10.2 ± 3.9, p = 0.004) groups after 6 months, without intergroup differences (p = 0.297; Table 2).”
Quoted verbatim from Potential Impact of Choline Alphoscerate on Depressive Symptoms in Association with Insulin Resistance in Elderly Patients with Type 2 Diabetes.
This finding among the 6 findings on its endpoint

sn-glycerol 3-phosphocholine

Hamilton Depression Rating Scale (HDRS) total score

no difference found

Who
Patients with type 2 diabetes aged 50 years or older with mild depressive symptoms (BDI 10 or more), outpatient clinic, Korea; 6-month double-blind trial, 2:1 allocation
Dose studied
choline alphoscerate 800 mg/day (400 mg twice daily with a meal) versus placebo

Moderate evidencePMID 40095622 · 2025

02 · The study

Study
RCT
Duration
6 months

Evidence, by strength

  • strong
  • moderatethis finding
  • limited
  • very limited
  • insufficient

03 · The paper

Journal of clinical medicine
What else it reported1 finding · 1 compound · 1 endpoint

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M6ZFAMDM43YRJTSC5TF5KEVP